Inmune Bio, Inc.
7 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of INKmune in Patients With mCRPC (CaRe Prostate) (NCT06056791) | Inmune Bio, Inc. | 2023-11-30 |
| Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation (NCT05321498) | Inmune Bio, Inc. | 2023-06-01 |
| An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease (NCT05522387) | Inmune Bio, Inc. | 2023-02-21 |
| A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation (NCT05318976) | Inmune Bio, Inc. | 2022-02-28 |
| INB03 for the Treatment of Pulmonary Complications From COVID-19 (NCT04370236) | Inmune Bio, Inc. | 2020-10-21 |
| A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (NCT05933070) | Inmune Bio, Inc. | 2020-06-15 |
| A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's (NCT03943264) | Inmune Bio, Inc. | 2019-11-20 |
Track Inmune Bio, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.